Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)

Design Therapeutics' Operating Expenses history spans 2 years, with the latest figure at $11.1 million for Q4 2021.

  • On a quarterly basis, Operating Expenses rose 185.75% to $11.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $35.8 million, a 318.78% increase, with the full-year FY2025 number at $79.5 million, up 27.39% from a year prior.
  • Operating Expenses hit $11.1 million in Q4 2021 for Design Therapeutics, down from $11.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for DSGN hit a ceiling of $11.3 million in Q3 2021 and a floor of $765000.0 in Q1 2020.